诺乙雄龙
诺乙雄龙结构式
|
常用名 | 诺乙雄龙 | 英文名 | norethandrolone |
|---|---|---|---|---|
| CAS号 | 52-78-8 | 分子量 | 302.451 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | 447.1±45.0 °C at 760 mmHg | |
| 分子式 | C20H30O2 | 熔点 | 130-136ºC | |
| MSDS | N/A | 闪点 | 190.5±21.3 °C | |
| 符号 |
GHS02, GHS07, GHS08 |
信号词 | Danger |
| 中文名 | 乙诺酮 |
|---|---|
| 英文名 | (8R,9S,10R,13S,14S,17S)-17-ethyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
| 中文别名 | 乙基去甲睾酮'诺乙龙 | 诺乙雄龙 |
| 英文别名 | 更多 |
| 密度 | 1.1±0.1 g/cm3 |
|---|---|
| 沸点 | 447.1±45.0 °C at 760 mmHg |
| 熔点 | 130-136ºC |
| 分子式 | C20H30O2 |
| 分子量 | 302.451 |
| 闪点 | 190.5±21.3 °C |
| 精确质量 | 302.224579 |
| PSA | 37.30000 |
| LogP | 4.07 |
| 蒸汽压 | 0.0±2.5 mmHg at 25°C |
| 折射率 | 1.555 |
| 储存条件 | ?20°C |
| 分子结构 | 1、 摩尔折射率：87.74 2、 摩尔体积（cm3/mol）：273.1 3、 等张比容（90.2K）：703.7 4、 表面张力（dyne/cm）：44.0 5、 极化率（10-24cm3）：34.78 |
| 计算化学 | 1.疏水参数计算参考值（XlogP）:无 2.氢键供体数量:1 3.氢键受体数量:2 4.可旋转化学键数量:1 5.互变异构体数量:8 6.拓扑分子极性表面积37.3 7.重原子数量:22 8.表面电荷:0 9.复杂度:522 10.同位素原子数量:0 11.确定原子立构中心数量:6 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 更多 | 1.熔点（℃）：130-136。 |
| 符号 |
GHS02, GHS07, GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H225-H315-H360FD |
| 补充危害声明 | May form explosive peroxides. |
| 警示性声明 | P201-P210-P280-P308 + P313-P370 + P378-P403 + P235 |
| 危害码 (欧洲) | F,T |
| 风险声明 (欧洲) | 60-61-11-19-38 |
| 安全声明 (欧洲) | 53-45 |
| 危险品运输编码 | UN2252 - class 3 - PG 2 - 1,2-Dimethoxyethane solution |
| 诺乙雄龙上游产品 3 | |
|---|---|
| 诺乙雄龙下游产品 1 | |
CAS号68-22-4
CAS号1042-57-5
CAS号734-32-7
CAS号6961-15-5|
[Tumors of the liver secondary to androgen therapy. Apropos of 2 cases in children].
Chir. Pediatr. 28(2) , 97-101, (1987) The authors report 2 cases of hepatocellular tumour in children treated with anabolic androgens for aplastic anemia. In both cases, the presentation was by a picture of acute abdomen due to hemoperito... |
|
|
Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits.
Exp. Toxicol. Pathol. 61(4) , 317-23, (2009) Among 15,000 forensic post-mortem examinations performed on the coroner's order over a 24-year period (January 1981-December 2004) in the area of Lyon, France (population: 2,000,000), 2250 cases of un... |
|
|
In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.
J. Neural Transm. Gen. Sect. 120(1) , 131-9, (2013) Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children and adolescents, with up to 5 % affected worldwide. Twin and family studies on ADHD show its... |
| (17α)-17-Hydroxy-19-norpregn-4-en-3-one |
| Estr-4-en-3-one, 17-ethyl-17-hydroxy-, (17β)- |
| Ethylnortestosteron |
| SC 5914 |
| Solevar |
| Nilevar |
| norethandrolone |
| EINECS 200-153-5 |
| 19-Nor-17α-pregn-4-en-3-one, 17-hydroxy- |
| 19-Norpregn-4-en-3-one, 17-hydroxy-, (17α)- |
| Nileva |
| 17a-Ethyl-17-hydroxy-4-norandrosten-3-one |
| 17-Ethyl-19-nortestosterone |
| noretandrolon |
| 17a-Ethyl-19-nortestosterone |
| Estr-4-en-3-one, 17α-ethyl-17-hydroxy- |
| Pronabol |
| 17α-Ethyl-19-nortestosterone |
| MFCD00198409 |
| 17a-Ethyl-17-hydroxy-19-norandrost-4-en-3-one |
| 17-ENT |
